Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Resmetirom in Metabolic Dysfunction Associated Steatohepatitis: NCT05500222 Clinical Landscape Report 2026
15 October 2026
NCT05500222 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
MG-1113 in Hemophilia: NCT05493631 Clinical Landscape Report 2026
15 October 2026
NCT05493631 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: NCT05500807 Clinical Landscape Report 2026
15 October 2026
NCT05500807 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dashatinib in Fibrosis, Liver: NCT05506488 Clinical Landscape Report 2026
15 October 2026
NCT05506488 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zampilimab in Idiopathic Pulmonary Fibrosis: NCT05513950 Clinical Landscape Report 2026
15 October 2026
NCT05513950 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zilucoplan in Myasthenia Gravis: NCT05514873 Clinical Landscape Report 2026
15 October 2026
NCT05514873 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Idiopathic Pulmonary Fibrosis: NCT05515627 Clinical Landscape Report 2026
15 October 2026
NCT05515627 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NUV-001 in Anemia, Sickle Cell: CTRI/2022/08/044979 Clinical Landscape Report 2026
15 October 2026
CTRI/2022/08/044979 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Hematologic Diseases: PACTR202209604592389 Clinical Landscape Report 2026
15 October 2026
PACTR202209604592389 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rapirosiran in Metabolic Dysfunction Associated Steatohepatitis: NCT05519475 Clinical Landscape Report 2026
15 October 2026
NCT05519475 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
GM-60106 in Metabolic Dysfunction Associated Steatohepatitis: NCT05517564 Clinical Landscape Report 2026
15 October 2026
NCT05517564 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Voxelotor in Hematologic Diseases: PACTR202209867711506 Clinical Landscape Report 2026
15 October 2026
PACTR202209867711506 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.